Chicago Capital LLC Sells 116,661 Shares of Dynavax Technologies Corporation $DVAX

Key Points

• Chicago Capital LLC reduced its holdings in Dynavax Technologies Corporation by 2.2%, selling 116,661 shares and holding approximately 4.35% of the company's stock, valued at $51.86 million.
• In Q1, several hedge funds increased their stake in Dynavax, with Woodline Partners LP growing its position by 48.4% to 1,178,763 shares valued at $15.29 million.
• Dynavax technologies reported earnings of $0.14 per share for Q2, exceeding analysts' estimates, with total revenue of $95.44 million compared to expectations of $87.55 million.

Chicago Capital LLC lowered its holdings in Dynavax Technologies Corporation (NASDAQ:DVAX - Free Report) by 2.2% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 5,227,909 shares of the biopharmaceutical company's stock after selling 116,661 shares during the period. Chicago Capital LLC owned about 4.35% of Dynavax Technologies worth $51,861,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also added to or reduced their stakes in the business. Exchange Traded Concepts LLC grew its position in Dynavax Technologies by 4.3% in the second quarter. Exchange Traded Concepts LLC now owns 133,601 shares of the biopharmaceutical company's stock valued at $1,325,000 after purchasing an additional 5,523 shares in the last quarter. Strs Ohio bought a new position in shares of Dynavax Technologies in the 1st quarter valued at about $250,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in shares of Dynavax Technologies by 7.1% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 450,089 shares of the biopharmaceutical company's stock valued at $5,838,000 after acquiring an additional 29,764 shares during the period. Woodline Partners LP grew its position in shares of Dynavax Technologies by 48.4% in the 1st quarter. Woodline Partners LP now owns 1,178,763 shares of the biopharmaceutical company's stock valued at $15,289,000 after acquiring an additional 384,288 shares during the period. Finally, Caxton Associates LLP bought a new position in shares of Dynavax Technologies in the 1st quarter valued at about $225,000. Institutional investors own 96.96% of the company's stock.

Insiders Place Their Bets

In other Dynavax Technologies news, Director Scott Dunseth Myers acquired 3,800 shares of the company's stock in a transaction on Friday, August 22nd. The stock was acquired at an average price of $10.82 per share, for a total transaction of $41,116.00. Following the purchase, the director directly owned 35,004 shares of the company's stock, valued at $378,743.28. This trade represents a 12.18% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 2.98% of the stock is owned by company insiders.

Dynavax Technologies Stock Performance

NASDAQ DVAX opened at $9.66 on Tuesday. The firm has a 50-day moving average of $10.37 and a 200-day moving average of $10.73. The company has a debt-to-equity ratio of 0.45, a quick ratio of 6.01 and a current ratio of 6.65. The stock has a market cap of $1.13 billion, a PE ratio of -21.00 and a beta of 1.24. Dynavax Technologies Corporation has a 52-week low of $9.20 and a 52-week high of $14.63.

Dynavax Technologies (NASDAQ:DVAX - Get Free Report) last posted its earnings results on Thursday, August 7th. The biopharmaceutical company reported $0.14 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.12 by $0.02. Dynavax Technologies had a negative net margin of 16.67% and a positive return on equity of 5.10%. The company had revenue of $95.44 million during the quarter, compared to analysts' expectations of $87.55 million. On average, sell-side analysts anticipate that Dynavax Technologies Corporation will post 0.32 EPS for the current year.

Analyst Upgrades and Downgrades

DVAX has been the subject of a number of analyst reports. Wall Street Zen raised shares of Dynavax Technologies from a "hold" rating to a "buy" rating in a research report on Saturday, August 9th. JMP Securities reissued a "market outperform" rating and issued a $32.00 price objective on shares of Dynavax Technologies in a research report on Friday, August 22nd. Three investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $24.33.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.

Want to see what other hedge funds are holding DVAX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Dynavax Technologies Corporation (NASDAQ:DVAX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.